CagriSema Explained: The Promise and the Missed Endpoint
CagriSema is an investigational weight-loss injection that is not FDA-approved or for sale. Here is the honest picture, including a strong result and one notable miss.
What is CagriSema?
CagriSema is an investigational once-weekly injection from Novo Nordisk that combines two drugs in one: cagrilintide, an amylin-based agent, and semaglutide, the familiar GLP-1. The idea is that pairing an amylin pathway with a GLP-1 pathway could improve appetite control beyond semaglutide alone. CagriSema is not FDA-approved and is not available for sale or at New Hope Weight Loss.
How does it work?
Semaglutide activates the GLP-1 receptor to reduce appetite and slow stomach emptying. Cagrilintide mimics amylin, a hormone that also signals fullness. Combining the two is meant to give a complementary, two-pathway effect on appetite and food intake.
Ready to start?
$199 Skeptics’ Trial, see if it works for you
One month of medical-grade compounded semaglutide, the $119 doctor review, and a free B-12/lipotropic injection. No long-term commitment.
Start the 30-day trialWhat did the trials show, honestly?
The data is genuinely mixed, and an honest clinic says so. In REIMAGINE 2, CagriSema produced about 14.2% average weight loss at 68 weeks in people with type 2 diabetes. In REDEFINE 4 (reported in a Novo Nordisk 6-K filing in February 2026), it produced about 23% weight loss at 84 weeks, a strong number, but it missed the trial's non-inferiority endpoint against tirzepatide 15 mg, meaning it did not statistically prove it was at least as good as high-dose tirzepatide in that head-to-head comparison. Strong absolute loss, one important missed comparison: both parts of that picture matter.
Is CagriSema FDA-approved?
No. CagriSema is investigational. A new drug application has been filed, but it has not been approved, and it is not available for sale or at any clinic. Possible approval has been discussed for the 2026 to 2027 window, but timelines and prices are projections, not guarantees, and no legitimate clinic can offer it now.
What you can start today at New Hope Weight Loss
What a licensed clinic can legitimately offer right now is physician-supervised, compounded GLP-1 care. After a one-time $119 medical review with Dr. Sharma, eligible patients receive compounded semaglutide from $166 a month or compounded tirzepatide from $233 a month, with a $199 one-month Skeptics' Trial if you want to test the waters first. Compounded semaglutide and tirzepatide are prepared by licensed U.S. pharmacies and are not FDA-approved, not brand-identical, and not reviewed by the FDA for safety, effectiveness, or quality. Care is delivered in person in Orange County and by telehealth across California and additional states.
Frequently asked questions
Is CagriSema FDA-approved or available?
No. CagriSema is investigational. A new drug application has been filed, but it is not FDA-approved, not for sale, and not offered at New Hope Weight Loss. It is only available through the manufacturer's clinical trials.
How much weight did people lose on CagriSema?
In REIMAGINE 2, about 14.2% at 68 weeks in people with type 2 diabetes. In REDEFINE 4 (Novo Nordisk 6-K, February 2026), about 23% at 84 weeks. However, REDEFINE 4 missed its non-inferiority endpoint against tirzepatide 15 mg, so it did not statistically prove it matched high-dose tirzepatide in that comparison.
What does 'missed the non-inferiority endpoint' mean?
It means the trial was designed to prove CagriSema was at least as good as tirzepatide 15 mg, and the result did not statistically meet that bar. The absolute weight loss was still strong, but the specific head-to-head claim was not established. Honest reporting includes both facts.
Can I get CagriSema at New Hope Weight Loss?
No. We do not offer, sell, or take deposits for any investigational drug, including CagriSema. What we provide today is physician-supervised compounded semaglutide and tirzepatide, with honest updates as new options are approved.
What can I take for weight loss now?
Eligible patients can start physician-supervised compounded semaglutide from $166 a month or compounded tirzepatide from $233 a month after a $119 review, with a $199 trial option. These are not FDA-approved or brand-identical, and your physician confirms whether they are right for you.
This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.